



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

APPLICATION OF:

Zalipsky, et al.

APPLICATION No.: 10/714,085

FILED: November 14, 2003

FOR: METHOD FOR TREATING MULTI-DRUG
RESISTANT TUMORS

EXAMINER: Unknown

ART UNIT: 1615

CONFIRM. No.: 9528

Request for Corrected Filing Receipt

Application Processing Division/
Customer Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Attached is a copy of an official filing receipt received from the U.S. Patent and Trademark Office for which a corrected filing receipt is respectfully requested.
2. There is an error in the priority information, which was incorrectly entered. The priority information should read

This appln claims the benefit of 60/467,070 04/30/2003
and is a CIP of 10/057,839 01/25/2002
which is a CON of 09/556,610 04/21/2000 PAT 6,365,179
which claims the benefit of 60/130,897 01/23/1999

3. Enclosed is a copy of the transmittal and first page of the patent application as filed, showing the correct priority information. Also enclosed is a redlined copy of the Filing Receipt showing the requested change.

Respectfully submitted,

Date: April 30, 2004

Judy M.
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 PO Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/714,085	11/14/2003	1615	770	55325-8167.US06	24	10	2

22918
 PERKINS COIE LLP
 P.O. BOX 2168
 MENLO PARK, CA 94026



CONFIRMATION NO. 9528

FILING RECEIPT



OC000000011961203

Date Mailed: 02/24/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Samuel Zalipsky, Redwood City, CA;
 Alberto Gabizon, Jerusalem, ISRAEL;

Assignment For Published Patent Application

ALZA Corporation;

Domestic Priority data as claimed by applicant

CIP This appln claims benefit of 60/467,070 04/30/2003
 and is a CON of 10/057,839 01/25/2002
 which is a CON of 09/556,610 04/21/2000 PAT. 6,365,179
 which claims benefit of 60/130,897 04/23/1999

Foreign Applications

If Required, Foreign Filing License Granted: 02/24/2004

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

Title

Method for treating multi-drug resistant tumors

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).